Genetic Engineering & Biotechnology News (GEN), the leading life sciences publication, recently interviewed our CEO Daniela Marino.
The article reports on CUTISS’s progress with denovoSkin™ and the clinical trials, how the company plans to restore patients’ own skin pigmentation, the key role of automation to meet the scale up challenge, and CUTISS’s global ambitions.
“The product we are developing really can replace autografting—the current standard-of-care treatment—not only for severe burns patients but also for other reconstructive surgeries,” said Daniela in the interview.
You can read the full article using the link below.
